UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 25, 2005
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
Commission file number 333-92383
CHARLES RIVER LABORATORIESINTERNATIONAL, INC.
(Exact Name of Registrant as specified in its Charter)
DELAWARE
06-1397316
(State of Incorporation)
(I.R.S. Employer Identification No.)
251 BALLARDVALE STREET,WILMINGTON, MASSACHUSETTS
01887
(Address of Principal Executive Offices)
(Zip Code)
978-658-6000(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes x No o
As of July 20, 2005, there were 71,779,511 shares of the registrant’s common stock outstanding.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.FORM 10-QFor the Quarterly Period Ended June 25, 2005Table of Contents
Page
Part I.
Financial Information
Item 1.
Financial Statements
Condensed Consolidated Statements of Income (Unaudited) for the three months ended June 25, 2005 and June 26, 2004
3
Condensed Consolidated Statements of Income (Unaudited) for the six months ended June 25, 2005 and June 26, 2004
4
Condensed Consolidated Balance Sheets (Unaudited) as of June 25, 2005 and December 25, 2004
5
Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 25, 2005 and June 26, 2004
6
Notes to Unaudited Condensed Consolidated Interim Financial Statements
7
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
20
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
28
Item 4.
Controls and Procedures
29
Part II.
Other Information
Submission of Matters to a Vote of Security Holders
Item 6.
Exhibits
30
Special Note on Factors Affecting Future Results
This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. (Charles River) that are based on current expectations, estimates, forecasts and projections about the industries in which Charles River operates and the beliefs and assumptions of the management of Charles River. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Charles River’s Annual Report on Form 10-K for the year ended December 25, 2004 under the section entitled “Risks Related to Our Business and Industry.” Charles River undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
2
Part I. Financial Information
Item 1. Financial Statements
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in thousands, except per share amounts)
Three Months Ended
June 25,2005
June 26,2004
Net sales related to products
$
95,721
86,692
Net sales related to services
187,692
93,501
Total net sales
283,413
180,193
Costs and expenses
Cost of products sold
51,076
45,354
Cost of services provided
120,551
60,218
Selling, general and administrative
47,615
29,220
Amortization of intangibles
14,318
1,198
Operating income
49,853
44,203
Other income (expense)
Interest income
943
809
Interest expense
(5,714
)
(2,119
Other, net
(340
(73
Income before income taxes and minority interests
44,742
42,820
Provision for income taxes
12,460
16,058
Income before minority interests
32,282
26,762
Minority interests
(422
(462
Net income
31,860
26,300
Earnings per common share
Basic
0.46
0.57
Diluted
0.44
0.52
See Notes to Condensed Consolidated Interim Financial Statements
Six Months Ended
188,696
174,712
368,439
178,118
557,135
352,830
100,277
92,423
240,461
116,958
92,467
57,340
28,681
2,389
95,249
83,720
1,930
1,510
(12,960
(4,235
(484
127
83,735
81,122
23,320
36,210
60,415
44,912
(907
(1,018
59,508
43,894
0.88
0.96
0.84
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(dollars in thousands)
December 25,2004
Assets
Current assets
Cash and cash equivalents
166,549
207,566
Trade receivables, net
210,308
201,794
Inventories
60,373
61,914
Other current assets
42,049
39,032
Total current assets
479,279
510,306
Property, plant and equipment, net
349,623
357,149
Goodwill, net
1,419,079
1,422,586
Other intangibles, net
226,500
256,294
Deferred tax asset
46,154
50,412
Other assets
27,372
30,088
Total assets
2,548,007
2,626,835
Liabilities and Shareholders’ Equity
Current liabilities
Current portion of long-term debt and capital lease obligations
80,868
80,865
Accounts payable
24,347
28,672
Accrued compensation
36,921
46,037
Deferred income
103,850
117,490
Accrued liabilities
42,527
51,722
Other current liabilities
27,707
24,329
Total current liabilities
316,220
349,115
Long-term debt and capital lease obligations
325,677
605,980
Other long-term liabilities
165,236
189,443
Total liabilities
807,133
1,144,538
Commitments and contingencies
9,191
9,792
Shareholders’ equity
Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding
—
Common stock, $0.01 par value; 120,000,000 shares authorized; 71,628,688 and 65,785,328 shares issued and outstanding at June 25, 2005 and December 25, 2004, respectively
717
658
Capital in excess of par value
1,758,556
1,518,854
Retained earnings (deficit)
(3,585
(63,093
Unearned compensation
(26,744
(11,607
Accumulated other comprehensive income
2,739
27,693
Total shareholders’ equity
1,731,683
1,472,505
Total liabilities and shareholders’ equity
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(dollars in thousands)
Cash flows relating to operating activities
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
50,783
15,533
Amortization of debt issuance costs and discounts
1,266
654
Amortization of premiums on marketable securities
21
132
Provision for doubtful accounts
(179
545
907
1,018
Deferred income taxes
(1,977
9,865
Tax benefit from exercises of employee stock options
3,518
2,737
Loss (gain) on disposal of property, plant, and equipment
200
503
Non-cash compensation
9,049
1,589
Changes in assets and liabilities:
Trade receivables
(13,361
(12,958
(341
(2,801
(3,109
1,132
600
(1,857
(3,120
(3,420
(7,960
2,646
(13,703
2,507
(8,100
3,573
8,812
2,099
(18
800
Net cash provided by operating activities
82,796
68,191
Cash flows relating to investing activities
Acquisition of businesses
(3,432
(16,972
Capital expenditures
(24,249
(11,867
Purchases of marketable securities
(1,904
(9,243
Proceeds from sale of marketable securities
408
7,362
Proceeds from sale of property, plant and equipment
107
Net cash used in investing activities
(29,070
(30,720
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit agreement
94,000
Payments on long-term debt, capital lease obligation and revolving credit agreement
(95,263
(94,196
Proceeds from exercises of employee stock options
14,018
7,922
Dividends paid to minority interests
(1,350
(1,513
Payment of deferred financing costs
(635
(100
Net cash (used in) provided by financing activities
(83,230
6,113
Effect of exchange rate changes on cash and cash equivalents
(11,513
(1,762
Net change in cash and cash equivalents
(41,017
41,822
Cash and cash equivalents, beginning of period
182,331
Cash and cash equivalents, end of period
224,153
Supplemental schedule of noncash investing and financing activities:
Conversion of senior convertible debenture to common stock
198,020
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (dollars in thousands, except per share amounts)
1. Basis of Presentation
The condensed consolidated interim financial statements are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to present fairly the financial position and results of operations of Charles River Laboratories International, Inc. (the “Company”). The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 25, 2004.
Certain amounts in prior-year financial statements and related notes have been reclassified to conform with the current year presentation.
2. Business Acquisitions
On October 20, 2004, the Company’s shareholders approved the merger agreement with Inveresk Research Group (Inveresk). The acquisition strengthened the Company’s position as a leading global company providing essential preclinical and clinical drug development services and products. The strategic combination significantly expanded the Company’s service portfolio and strengthens the Company’s global footprint in the growing market for pharmaceutical research and development products and services. Under the terms of the merger agreement, Inveresk shareholders received 0.48 shares of the Company’s common stock and $15.15 in cash for each share of Inveresk common stock they owned. The purchase price of $1,458,057 consisted of $841,042 representing the fair value of the Company’s common stock of 18,451,996 shares issued, $582,391 of cash consideration, the fair value of the Company’s stock options exchanged for Inveresk stock options and transaction costs incurred by the Company. The Company utilized approximately $161,229 of available cash and $500,000 of borrowings under the credit facility for the cash consideration paid to Inveresk shareholders and to pay off Inveresk’s existing credit facility of $78,838.
The purchase price associated with the Inveresk acquisition is as follows:
Stock consideration
841,042
Cash consideration
582,391
Fair value of stock options exchange
30,350
Transaction costs
4,274
Purchase price
1,458,057
Cash acquired
(41,726
Purchase price, net of cash acquired
1,416,331
The Company’s purchase price allocation has not been finalized as the Company is awaiting the completion by an outside appraiser of the valuations of certain equipment. The outside appraisal of the
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued) (dollars in thousands, except per share amounts)
2. Business Acquisitions (Continued)
intangible assets acquired has been finalized. The Company does not anticipate any significant differences between current book values and the fair values upon the completion of the asset valuation.
The preliminary purchase price allocation associated with the Inveresk acquisition is as follows:
98,852
Property, plant and equipment
126,746
(198,691
Non-current liabilities
(147,505
Goodwill and other intangibles acquired
1,536,929
Total purchase price allocation
Weightedaverageamortizationlife (years)
Customer relationships
167,700
Backlog
63,700
Trademarks and trade names
700
1
Goodwill
1,304,829
Total goodwill and other intangibles
The following selected unaudited pro forma consolidated results of operations are presented as if the acquisition had occurred as of the beginning of the period immediately preceding the year of acquisition, after giving effect to certain adjustments for amortization of intangibles and related income tax effects. The pro forma data is for informational purposes only and does not necessarily reflect the results of operations had the companies operated as one during the periods reported. No effect has been given in the pro-forma data for synergies, if any, that may have been realized through the acquisition.
June 25, 2005
June 26, 2004
(as reported)
(pro forma)
Net sales
258,515
507,181
42,890
79,989
25,406
41,481
0.42
0.68
0.39
0.64
Refer to Note 7 for further discussion of the method of computation of earnings per share.
8
3. Impairment and Other Charges
During the fourth quarter of 2004, the Company recorded a charge of $2,956 associated with the closure of the Charles River Proteomic Services business, which was included in the Preclinical Services segment. The charge includes an asset impairment charge of $1,539, a lease impairment charge of $989, severance of $41 and other related expenses of $387.
4. Supplemental Balance Sheet Information
The composition of trade receivables is as follows:
Customer receivables
154,445
155,549
Unbilled revenue
58,377
50,082
Total
212,822
205,631
Less allowance for doubtful accounts
(2,514
(3,837
Net trade receivables
The composition of inventories is as follows:
Raw materials and supplies
9,411
9,393
Work in process
3,630
3,431
Finished products
47,332
49,090
The composition of other current assets is as follows:
Prepaid assets
17,069
16,045
10,675
Prepaid income tax
11,437
8,551
Restricted cash
2,628
3,527
Marketable securities
240
234
9
4. Supplemental Balance Sheet Information (Continued)
The composition of net property, plant and equipment is as follows:
Land
15,752
16,196
Buildings
286,445
282,733
Machinery and equipment
236,357
234,043
Leasehold improvements
20,719
19,926
Furniture and fixtures
7,133
6,401
Vehicles
4,489
4,547
Construction in progress
34,773
37,711
605,668
601,557
Less accumulated depreciation
(256,045
(244,408
Net property, plant and equipment
Depreciation expense for the six months ended June 25, 2005 and June 26, 2004 was $22,102 and $13,144, respectively.
The composition of other assets is as follows:
Deferred financing costs
6,993
10,454
Cash surrender value of life insurance policies
7,413
7,391
Long-term marketable securities
5,864
4,345
Pension asset
2,081
3,801
5,021
4,097
The composition of other current liabilities is as follows:
Accrued income taxes
23,938
18,027
Accrued interest
3,769
6,302
10
The composition of other long-term liabilities is as follows:
Deferred tax liability
72,684
93,143
Long-term pension liability
59,426
63,783
Accrued Executive Supplemental Life Insurance Retirement Plan
17,136
16,326
15,990
16,191
5. Goodwill and Other Intangible Assets
The following table displays goodwill and other intangible assets not subject to amortization and other intangible assets that continue to be subject to amortization:
December 25, 2004
GrossCarryingAmount
AccumulatedAmortization
1,431,774
(12,695
1,435,414
(12,828
Other intangible assets not subject to amortization:
Research models
3,438
Other intangible assets subject to amortization:
63,900
(29,800
65,368
(11,040
199,168
(18,000
202,956
(9,823
Customer contracts
1,655
(1,493
(1,429
3,918
(1,841
3,939
(1,377
Standard operating procedures
1,351
(943
1,358
(690
Other identifiable intangible assets
9,528
(4,381
6,158
(4,219
Total other intangible assets
282,958
(56,458
284,872
(28,578
11
5. Goodwill and Other Intangible Assets (Continued)
The changes in the gross carrying amount and accumulated amortization of goodwill are as follows:
Adjustments to Goodwill
Balance atDecember 25, 2004
Acquisitions
Other
Balance atJune 25, 2004
Research Models and Services
Gross carrying amount
19,921
(601
19,320
Accumulated amortization
(4,900
133
(4,767
Preclinical Services
1,036,599
(1,210
(1,336
1,034,053
(7,928
Clinical Services
378,894
(493
378,401
(1,703
(1,937
6. Long-Term Debt
During the second quarter of 2005, the Company converted all of its $185 million 3.5% senior convertible debentures due February 1, 2022 into 4,759,424 shares of common stock. The Company recorded additional equity of $198.0 million due to the conversion, which represented the book value of the debentures ($185 million), deferred tax liability associated with the debentures ($14.5 million) and accrued interest ($1.3 million), partially offset by the deferred financing costs ($2.8 million).
Effective May 6, 2005, the Company amended the credit agreement, entered into during the fourth quarter of 2004, to reduce the interest rate by 0.50% and modify certain restrictive covenants. The credit agreement provides for a $400,000 term loan facility and a $150,000 revolving facility. The term loan facility matures in 20 equal, quarterly installments with the first installment payable December 31, 2004 and the last installment due September 30, 2009. The revolver facility matures on October 15, 2009 and requires no scheduled prepayment before that date. The interest rates applicable to term loans and revolving loans under the credit agreement are, at the Company’s option, equal to either the base rate (which is the higher of the prime rate or the federal funds rate plus ½%) or the adjusted LIBOR rate plus an interest rate margin based upon the Company’s leverage ratio which was 1% as of June 25, 2005. Based on the leverage ratio of the Company, the margin range for LIBOR based loans is 0.75% to 1.25%. The credit agreement includes certain customary representations and warranties, negative and affirmative covenants and events of default. The Company was in compliance with its debt covenants as of June 25, 2005. The Company had $4,988 outstanding under letters of credit as of June 25, 2005 and December 25, 2004, respectively.
12
7. Shareholders’ Equity
Earnings per Share
Basic earnings per share for the three and six months ended June 25, 2005 and June 26, 2004 were computed by dividing earnings available to common shareholders for these periods by the weighted average number of common shares outstanding in the respective periods. The weighted average number of common shares outstanding in the three and six months ended June 25, 2005 and June 26, 2004 have been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share for this period.
Options to purchase 1,020,190 and 26,800 shares were outstanding in each of the respective three months ended June 25, 2005 and June 26, 2004 but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase 1,250,044 and 1,320,600 shares were outstanding in each of the respective six months ended June 25, 2005 and June 26, 2004 but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive.
Basic weighted average shares outstanding for the three and six months ended June 25, 2005 and June 26, 2004 excluded the weighted average impact of 590,991 and 90,839 shares, respectively, of non-vested fixed restricted stock awards.
13
7. Shareholders’ Equity (Continued)
The following table illustrates the reconciliation of the numerator and denominator of the basic and diluted earnings per share computations:
Numerator:
Net income for purposes of calculating earnings per share
After-tax equivalent of interest expense on 3.5% senior convertible debentures
295
995
1,463
1,991
Income for purposes of calculating diluted earnings per share
32,155
27,295
60,971
45,885
Denominator:
Weighted average shares outstanding—Basic
69,738,107
46,046,675
67,807,103
45,950,897
Effect of dilutive securities:
3.5% senior convertible debentures
1,202,939
4,759,455
2,981,197
Stock options and contingently issued restricted stock
1,633,092
1,440,297
1,604,147
1,294,509
Warrants
342,096
339,860
341,651
337,175
Weighted average shares outstanding—Diluted
72,916,234
52,586,287
72,734,098
52,342,036
Basic earnings per share
Diluted earnings per share
Comprehensive Income
The components of comprehensive income (net of tax) are set forth below:
Foreign currency translation adjustment
(26,696
(4,998
(25,169
(1,579
Net unrealized gain (loss) on marketable securities
80
(98
55
(124
Net unrealized gain on hedging contracts
160
Comprehensive income
5,404
21,204
34,554
42,191
14
8. Income Taxes
The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statement of income:
Income before income taxes and minority interest
Effective tax rate
27.85
%
37.50
Provision at effective tax rate
30,421
Effect of:
Deferred tax asset write-off
7,900
Valuation allowance release
(2,111
On October 22, 2004, the American Jobs Creation Act of 2004 (the “Act”) was signed into law. The Act creates a temporary incentive for U.S. multinationals to repatriate accumulated income earned outside the U.S. at an effective tax rate of 5.25%. This provision is applicable to our fiscal year 2005. The Company is currently in the process of evaluating whether or not, and to what extent, if any, this provision may benefit the Company. If the Company decides to repatriate all of the pre-acquisition earnings of Inveresk in a distribution that qualifies for the reduced tax rate under the Act, the Company estimates it will recognize a one-time tax benefit of $21,533 in the quarter in which the decision is made.
In the first quarter of 2004, the Company reorganized its European operations. The purpose of the reorganization was to streamline the legal entity structure in order to improve operating efficiency and cash management, facilitate acquisitions and provide tax benefits. The reorganization, which did not involve reductions of personnel or facility closures, resulted in a one-time, non-cash charge to earnings in the first quarter of 2004 of $7,900 due primarily to the write-off of a deferred tax asset. In light of this reorganization, the Company reassessed the valuation allowance associated with its foreign tax credit carryforwards. As a result of this reassessment, $2,111 of the valuation allowance was released and recorded as a tax benefit.
15
9. Employee Benefits
The following table provides the components of net periodic benefit cost for the Company’s defined benefit plans:
Pension Benefits
Service cost
1,368
665
2,787
1,626
Interest cost
2,248
621
4,535
1,300
Expected return on plan assets
(2,048
(827
(4,122
(1,671
Amortization of transition obligation
Amortization of prior service cost
(135
71
(274
144
Amortization of net loss (gain)
156
(7
322
38
Net periodic benefit cost
524
3,248
1,439
Company contributions
1,203
193
2,479
383
Supplemental Retirement Benefits
130
53
225
142
262
207
505
416
(40
(80
(81
232
148
427
291
584
368
1,077
768
10. Stock-Based Compensation Plans
SFAS No. 123, “Accounting for Stock-Based Compensation,” requires the presentation of certain pro forma information as if the Company had accounted for its employee stock options under the fair value method. For purposes of this disclosure, the fair value of the fixed option grants was estimated using the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility and expected life of the options. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimates, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. However, for each period presented, management believes the Black-Scholes model is the most appropriate option valuation model for the Company’s options.
Had compensation expense for the Company’s option grants been determined consistent with the provision of SFAS No. 123, as amended by SFAS No. 148, “Accounting for Stock-Based Compensation-
16
10. Stock-Based Compensation Plans (Continued)
Transition and Disclosure, an Amendment of FASB Statement No. 123,” the Company’s net income would have been reduced to the pro forma amounts indicated below:
June 26, 2005
Reported net income
Add: Stock-based employee compensation included in reported net income, net of tax
3,543
619
6,543
993
Less: Total stock-based employee compensation expense determined under the fair value method for all awards, net of tax
(9,579
(5,255
(16,935
(9,467
Pro forma net income
25,824
21,664
49,116
35,420
Reported basic earnings per share
Pro forma basic earnings per share
0.37
0.47
0.72
0.77
Reported diluted earnings per share
Pro forma diluted earnings per share
0.36
0.43
0.70
0.71
Restricted Common Stock and Performance Based Plans
Under the Company’s 2000 Incentive Plan, restricted common stock of the Company may be granted at no cost to officers and key employees. Holders of restricted common stock are entitled to cash dividends, if declared, and to vote their respective shares. Restrictions limit the sale or transfer of these shares until they vest, which is typically over a three-year period. Upon issuance of restricted stock awards under the plan, unearned compensation equivalent to the market value at the date of grant is charged to shareholders’ equity and subsequently amortized to expense over the vesting period. During the six months ended June 25, 2005, the Company granted 518,680 restricted stock awards and recorded $24,735 as unearned compensation in shareholders’ equity. During the three months ended June 25, 2005 and June 26, 2004, the Company recorded $2,244 and $505, respectively, and during the six months ended June 25, 2005 and June 26, 2004, the Company recorded $3,255 and $927, respectively, in compensation expense for restricted stock awards.
The Company will accrue compensation expense for the performance-based management incentive program (Mid-Term Incentive (MTI) Program) based on achieving certain financial targets in 2006. The expense will be recognized over the period the participating employees are required to be employed by the Company. During the six months ended June 25, 2005 and June 26, 2004, the Company recorded $38 and $1,316, respectively, as compensation expense of which $19 and $662, respectively, was recorded as capital in excess of par value and $19 and $654, respectively, was recorded as accrued compensation. In February 2005, the Compensation Committee of the Board of Directors determined that it would not make any future awards under the MTI Program.
17
11. Commitments and Contingencies
Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect the Company’s consolidated financial statements.
12. Business Segment Information
The following table presents sales to unaffiliated customers and other financial information by product line segment.
130,771
120,085
258,683
239,562
Gross margin
57,755
54,277
114,341
107,048
43,050
41,041
85,358
79,792
5,047
4,296
9,776
8,605
6,516
4,952
11,791
8,395
119,107
60,108
233,179
113,268
42,962
20,344
81,150
36,401
17,717
11,397
30,233
18,971
16,596
3,400
33,589
6,928
5,176
2,390
12,199
3,472
33,535
65,273
11,069
20,906
1,948
2,781
3,714
7,418
159
259
18
12. Business Segment Information (Continued)
A reconciliation of segment operating income to consolidated operating income is as follows:
Total segment operating income
62,715
52,438
118,372
98,763
Unallocated corporate overhead
(12,862
(8,235
(23,123
(15,043
Consolidated operating income
A summary of unallocated corporate overhead consists of the following:
Restricted stock and performance based compensation expense
4,753
1,527
9,087
2,243
U.S. pension expense
1,367
641
2,685
1,741
Audit, tax and related expenses
831
1,066
1,353
2,146
Executive officers’ salary
461
396
922
799
Other general unallocated corporate expenses
5,450
4,605
9,076
8,114
12,862
8,235
23,123
15,043
Other general unallocated corporate expenses consist of various departmental costs including corporate accounting, legal and investor relations.
13. Recently Issued Accounting Standards
On December 16, 2004, the Financial Accounting Standards Board issued SFAS No. 123 (revised 2004), “Shared-Based Payment,” which is a revision of SFAS No. 123. SFAS No. 123(R) supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and amends SFAS No. 95, “Statement of Cash Flows.” Generally, the approach in SFAS No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. This revised standard will be effective for the Company for the first quarter of 2006.
As permitted by SFAS No. 123, the Company currently accounts for share-based payments to employees using APB 25 intrinsic value method and, as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123(R)’s fair value method will have an impact on the Company’s result of operations, although it will have no impact on the Company’s overall financial position. The impact of the modified prospective adoption of SFAS No. 123(R) cannot be estimated at this time because it will depend on levels of share-based payments granted in the future. However, had the Company adopted SFAS No. 123(R) in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net income and earnings per share.
19
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes.
Overview
We are a leading global provider of solutions that advance the drug discovery and development process. These solutions include research models and outsourced preclinical and clinical services, and are designed to enable our clients to bring drugs to market faster and more efficiently. Our products and services are organized into three categories spanning every step of the drug development pipeline: Research Models and Services (RMS), Preclinical Services, and Clinical Services. We have been in business for more than 55 years, and our customer base includes all of the major pharmaceutical companies and many biotechnology companies, government agencies, leading hospitals and academic institutions.
Our second quarter sales growth was driven by the Inveresk acquisition and continued strong spending by major pharmaceuticals, biotechnology companies and academic institutions on our global products and services, which aid in their development of new drugs and products. We continue to see strong customer demand for toxicology services and specialty research models in our markets, partially offset by reduced market demand for our interventional and surgical services. We continue to make progress in presenting our unified strong brand name to our customers, identifying our best practices and optimizing our management talent. We remain on target to achieve our cost savings goal of $10 million in 2005. Finally, our growth strategy has long included the acquisition of companies to serve as growth platforms. We continue to assess near and long-term opportunities to add new platforms through acquisitions that complement our business and increase the rate of our growth.
Total net sales in the second quarter of 2005 were $283.4 million, an increase of 57.3% over the same period last year. The sales increase was due to the acquisition of Inveresk Research Group in the fourth quarter of 2004, strong customer demand, increased pricing and favorable foreign exchange. Our gross margin decreased to 39.4% of net sales, compared to 41.4% of net sales for the same period last year due to the addition of more Preclinical and Clinical sales to the sales mix and a decline in the Research Model and Services gross margin rate. The RMS gross margin rate declined mainly due to the impact of lower transgenic and vaccine product sales. Operating income was $49.9 million, an increase of $5.7 million, or 12.8%, compared to $44.2 million for the same period last year. The operating margin was 17.6%, compared to 24.5% for the same period last year. Operating income was unfavorably impacted by charges related to the acquisition of Inveresk, including amortization of intangibles of $13.1 million and stock based compensation of $2.8 million. Net income in the second quarter of 2005 was $31.9 million, compared to $26.3 million in the same period last year. Diluted earnings per share for the second quarter of 2005 were $0.44, compared to $0.52 in the same period last year. The unfavorable impact of amortization associated with the acquisition of Inveresk ($0.12) and Inveresk related stock based compensation ($0.03) reduced diluted earnings per share by $0.15 in the second quarter of 2005.
On a year to date basis ending June 25, 2005, total net sales were $557.1 million, an increase of 57.9% over the same period last year. Our gross margin decreased to 38.8% of total net sales, compared to 40.7% of total net sales for the same period last year. Operating income on a year to date basis increased 13.8% over last year. Net income on a year to date basis was $59.5 million, compared to $43.9 million for the same period last year. Diluted earnings per share on a year to date basis were $0.84, compared to $0.88 in the same period last year. The unfavorable impact of amortization associated with the acquisition of Inveresk ($0.25) and Inveresk related stock based compensation ($0.05) reduced earnings per share by $0.30 on a year to date basis. In the first quarter of 2004, an unfavorable deferred tax adjustment related to the European reorganization ($0.15), partially offset by a favorable reversal of the tax valuation allowance ($0.04) decreased diluted earnings per share by $0.11.
Our RMS segment represented 46.1% of net sales in the second quarter of 2005. Net sales for this segment increased 8.9% over the same period last year. Favorable foreign currency translation contributed approximately 2% of the net sales gain. The RMS gross margin rate declined mainly due to the impact of lower transgenic and vaccine product sales. Operating income decreased to 32.9% of net sales, compared to 34.2% of net sales for the same period last year.
Sales on a year to date basis for our RMS business segment increased 8.0% over the same period last year. The net sales increase drove an improvement in operating income. Operating income was $85.4 million, an increase of $5.6 million, or 7.0%, from the same period last year. Operating income as a percent of net sales decreased to 33.0% compared to 33.3% for last year.
Our Preclinical Services segment represented 42.0% of net sales in the second quarter of 2005. Sales for this segment increased 98.2% over the same period last year. Our sales results were favorably impacted by the acquisition of Inveresk. Favorable foreign currency translation contributed less than 1% of the net sales gain. We experienced favorable market conditions as demand for toxicology services remained strong, partially offset by reduced market demand for our interventional and surgical services. We continue to see improving levels of customer demand in certain of our Preclinical services businesses, particularly large model, reproductive, infusion and inhalation toxicology.
Sales on a year to date basis for our Preclinical Services segment increased 105.9% over the same period last year. Operating income decreased to 13.0% of net sales, compared to 16.7% for the first six months of 2004 due to the amortization of intangible s relating to the Inveresk acquisition.
Our Clinical Services segment represented 11.8% of net sales in the second quarter of 2005. Operating income was 5.8% of net sales for the second quarter of 2005. We acquired the clinical service business with the acquisition of Inveresk during the fourth quarter of 2004.
Three Months Ended June 25, 2005 Compared to Three Months Ended June 26, 2004
Net Sales. Net sales for the three months ended June 25, 2005 were $283.4 million, an increase of $103.2 million, or 57.3%, from $180.2 million for the three months ended June 26, 2004.
Research Models and Services. For the three months ended June 25, 2005, net sales for our RMS segment were $130.8 million, an increase of $10.7 million, or 8.9%, from $120.1 million for the three months ended June 26, 2004. RMS global prices increased in a range up to 5% with the weighted average increase approximately 3%. Increased unit volume of both models and services added approximately 2% to the net sales increase. Favorable foreign currency translation contributed approximately 2% to our net sales gain. The RMS sales increase was driven by higher spending on basic research by pharmaceutical and biotechnology companies, which drove greater demand for our products and services, partially offset by lower transgenic and vaccine product sales.
Preclinical Services. For the three months ended June 25, 2005, net sales for our Preclinical Services segment were $119.1 million, an increase of $59.0 million, or 98.2%, compared to $60.1 million for the three months ended June 26, 2004. The increase was primarily due to the acquisition of Inveresk in October 2004 and to increased customer demand for toxicology and other preclinical services, partially offset by reduced demand for our interventional and surgical services. Our preclinical services business benefited from increased customer demand, reflecting increased drug development efforts and customers outsourcing their preclinical service needs. Foreign currency contributed less than 1% to the sales growth.
Clinical Services. In the fourth quarter of 2004, we entered the clinical services business with the acquisition of Inveresk. For the three months ended June 25, 2005, net sales for our Clinical Services segment were $33.5 million.
Cost of Products Sold and Services Provided. Cost of products sold and services provided for the three months ended June 25, 2005 was $171.6 million, an increase of $66.0 million, or 62.6%, from $105.6 million
for the three months ended June 26, 2004. Cost of products sold and services provided for the three months ended June 25, 2005 was 60.6% of net sales, compared to 58.6% for the three months ended June 26, 2004 due to the mix of more Preclinical and Clinical sales and increased costs in the RMS segment. Cost of goods sold and services provided include the appropriate depreciation, facilities cost and other costs, which is a refinement of Inveresk’s pre-acquisition reporting where such costs were reported in selling, general and administrative expenses.
Research Models and Services. Cost of products sold and services provided for RMS for the three months ended June 25, 2005 was $73.0 million, an increase of $7.2 million, or 11.0%, compared to $65.8 million for the three months ended June 26, 2004. Cost of products sold and services provided increased as a percent of net sales to 55.8% for the three months ended June 25, 2005, compared to the three months ended June 26, 2004 at 54.8% of net sales. Lower transgenic and vaccine product sales along with higher fuel costs adversely effected the cost of products sold and services provided as a percent of sales.
Preclinical Services. Cost of products sold and services provided for the Preclinical Services segment for the three months ended June 25, 2005 was $ 76.1 million, an increase of $36.3 million, or 91.5%, compared to $39.8 million for the three months ended June 26, 2004. Cost of products sold and services provided as a percentage of net sales was 63.9% for the three months ended June 25, 2005, compared to 66.2% for the three months ended June 26, 2004. The decrease in cost of products sold and services provided as a percentage of net sales was primarily due to improved capacity utilization resulting from the increased sales of services.
Clinical Services. Cost of products sold and services provided for the Clinical Services segment for the three months ended June 25, 2005 was $22.5 million. Cost of products sold and services provided as a percentage of net sales was 67.0%.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended June 25, 2005 were $47.6 million, an increase of $18.4 million, or 62.6%, from $29.2 million for the three months ended June 26, 2004. Selling, general and administrative expenses for the three months ended June 25, 2005 were 16.8% of net sales compared to 16.2% of net sales for the three months ended June 26, 2004. The increase was due primarily to increased compensation expense for stock awards and the compensation charge recorded for Inveresk’s stock options. During the three months ended June 25, 2005, the Company granted 51,800 restricted stock awards and recorded $2.2 million as unearned compensation in shareholders’ equity, which will be amortized over three years.
Research Models and Services. Selling, general and administrative expenses for RMS for the three months ended June 25, 2005 were $ 14.6 million, an increase of $1.4 million, or 11.0%, compared to $13.2 million for the three months ended June 26, 2004. Selling, general and administrative expenses increased slightly as a percentage of sales to 11.2% for the three months ended June 25, 2005 from 11.0% for the three months ended June 26, 2004.
Preclinical Services. Selling, general and administrative expenses for the Preclinical Services segment for the three months ended June 25, 2005 were $14.0 million, an increase of $6.2 million, or 79.6%, compared to $7.8 million for the three months ended June 26, 2004 due mainly to the addition of Inveresk. Selling, general and administrative expenses for the three months ended June 25, 2005 decreased to 11.8% of net sales, compared to 13.0% of net sales for the three months ended June 26, 2004 due to greater economies of scale.
22
Clinical Services. Selling, general and administrative expenses for the Clinical Services segment for the three months ended June 25, 2005 were $6.1 million. Selling, general and administrative expenses for the Clinical Services segment were 18.3% of net sales.
Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various corporate expenses including those associated with pension, executive salaries, stock based compensation and departments such as corporate accounting, legal and investor relations, was $12.9 million for the three months ended June 25, 2005, compared to $8.2 million for the three months ended June 26, 2004. The increase in unallocated corporate overhead for the three months ended June 25, 2005 was due primarily to increased restricted stock expense and stock-based compensation relating to the acquisition of Inveresk.
Amortization of Other Intangibles. Amortization of other intangibles for the three months ended June 25, 2005 was $14.3 million, an increase of $13.1 million, from $1.2 million for the three months ended June 26, 2004. The increased amortization was due to the acquisition of Inveresk.
Preclinical Services. For the three months ended June 25, 2005, amortization of other intangibles for our Preclinical Services segment was $11.2 million, an increase of $10.0 million compared to the three months ended June 26, 2004. The increase in amortization of other intangibles was related to the acquisition of Inveresk.
Clinical Services. For the three months ended June 25, 2005, amortization of other intangibles for our Clinical Services segment was $3.0 million, related to the acquisition of Inveresk.
Operating Income. Operating income for the three months ended June 25, 2005 was $49.9 million, an increase of $5.7 million, or 12.8%, from $44.2 million for the three months ended June 26, 2004. Operating income for the three months ended June 25, 2005 was 17.6% of net sales, compared to 24.5% of net sales for the three months ended June 26, 2004. The decrease as a percent of sales was due primarily to the Inveresk related amortization of $13.1 million and the Inveresk stock based compensation charge of $2.8 million.
Research Models and Services. For the three months ended June 25, 2005, operating income for our RMS segment was $43.1 million, an increase of $2.1 million, or 4.9%, from $41.0 million for the three months ended June 26, 2004. Operating income as a percentage of net sales for the three months ended June 25, 2005 was 32.9%, compared to 34.2% for the three months ended June 26, 2004. The decrease in the operating income as a percentage of net sales was primarily due to higher cost of products sold and services provided.
Preclinical Services. For the three months ended June 25, 2005, operating income for our Preclinical Services segment was $17.7 million, an increase of $6.3 million, or 55.5%, from $11.4 million for the three months ended June 26, 2004. Operating income as a percentage of net sales decreased to 14.9%, compared to 19.0% of net sales for the three months ended June 26, 2004. The decrease in operating income for the three months ended June 25, 2005 was primarily due to Inveresk related amortization expense of 8.5% of net sales, partially offset by improved capacity utilization.
Clinical Services. For the three months ended June 25, 2005, operating income for our Clinical Services segment was $1.9 million. Operating income as a percentage of net sales was 5.8% for the three months ended June 25, 2005. The operating income as a percentage of net sales includes the Inveresk related amortization of 8.9% of net sales.
Interest Expense. Interest expense for the three months ended June 25, 2005 was $5.7 million, compared to $2.1 million for the three months ended June 26, 2004. The $3.6 million increase was primarily due to the increased borrowing as a result of the Inveresk acquisition.
Income Taxes. Income tax expense for the three months ended June 25, 2005 was $12.5 million, a decrease of $3.6 million compared to $16.1 million for the three months ended June 26, 2004. Our effective
23
tax rate for the three months ended June 25, 2005 was 27.85%. Excluding charges associated with the deferred tax write-off and the benefit from the reversal of the valuation allowance, the effective tax rate for the three months ended June 26, 2004 was 37.5%. The decrease in the effective tax rate was due primarily to the lower effective tax rates for our foreign operations.
Net Income. Net income for the three months ended June 25, 2005 was $31.9 million, an increase of $5.6 million from $26.3 million for the three months ended June 26, 2004.
Six Months Ended June 25, 2005 Compared to Six Months Ended June 26, 2004
Net Sales. Net sales for the six months ended June 25, 2005 were $557.1 million, an increase of $204.3 million, or 57.9%, from $352.8 million for the six months ended June 26, 2004.
Research Models and Services. For the six months ended June 25, 2005, net sales for our RMS segment were $258.7 million, an increase of $19.1 million, or 8.0%, from $239.6 million for the six months ended June 26, 2004. RMS global prices increased in a range up to 5% with the weighted average increase approximately 3%. Increased unit volume of both models and services added approximately 2% to the net sales increase. Favorable foreign currency translation contributed approximately 2% to our net sales gain. The RMS sales increase was driven by higher spending on basic research by pharmaceutical and biotechnology companies, which drove greater demand for our products and services, partially offset by lower transgenic services and vaccine product sales.
Preclinical Services. For the six months ended June 25, 2005, net sales for our Preclinical Services segment were $233.2 million, an increase of $119.9 million, or 105.9%, compared to $113.3 million for the six months ended June 26, 2004. The increase was primarily due to the acquisition of Inveresk and to increased customer demand for toxicology and other preclinical services, partially offset by reduced demand for our interventional and surgical services. Our preclinical services business benefited from increased customer demand, reflecting increased drug development efforts and customers outsourcing. Foreign currency contributed less than 1% to the sales growth.
Clinical Services. In the fourth quarter of 2004, we entered the clinical services business with the acquisition of Inveresk. For the six months ended June 25, 2005, net sales for our Clinical Services segment were $65.3 million.
Cost of Products Sold and Services Provided. Cost of products sold and services provided for the six months ended June 25, 2005 was $340.7 million, an increase of $131.3 million, or 62.7%, from $209.4 million for the six months ended June 26, 2004. Cost of products sold and services provided for the six months ended June 25, 2005 was 61.2% of net sales, compared to 59.3% for the six months ended June 26, 2004 due to the mix of more Preclinical and Clinical service sales and an increase in the RMS segment. Cost of goods sold and services provided include the appropriate depreciation, facilities cost and other costs, which is a refinement of Inveresk’s pre-acquisition reporting where such costs were reported in selling, general and administrative expenses.
Research Models and Services. Cost of products sold and services provided for RMS for the six months ended June 25, 2005 was $144.3 million, an increase of $11.8 million, or 8.9%, compared to $132.5 million for the six months ended June 26, 2004. Cost of products sold and services provided as a percent of net sales for the six months ended June 25, 2005 was 55.8% compared to the six months ended June 26, 2004 at 55.3% of net sales. Lower transgenic and vaccine product sales along with higher fuel costs adversely effected the cost of products sold and services provided as a percentage of sales.
Preclinical Services. Cost of products sold and services provided for the Preclinical Services segment for the six months ended June 25, 2005 was $152.0 million, an increase of $75.1 million, or 97.8%, compared to $76.9 million for the six months ended June 26, 2004. Cost of products sold and services provided as a percentage of net sales was 65.2% for the six months ended June 25, 2005, compared to
24
67.9% for the six months ended June 26, 2004. The decrease in cost of products sold and services provided as a percentage of net sales was primarily due to improved capacity utilization resulting from the increased sales of services.
Clinical Services. Cost of products sold and services provided for the Clinical Services segment for the six months ended June 25, 2005 was $44.4 million. Cost of products sold and services provided as a percentage of net sales was 68.0%.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended June 25, 2005 were $92.5 million, an increase of $35.2 million, or 61.3%, from $57.3 million for the six months ended June 26, 2004. Selling, general and administrative expenses for the six months ended June 25, 2005 were 16.6% of net sales compared to 16.3% of net sales for the six months ended June 26, 2004. The increase was due primarily to the compensation charge for Inveresk’s stock options and increased compensation expense for stock awards. During the six months ended June 25, 2005, the Company granted 518,680 restricted stock awards and recorded $24.7 million as unearned compensation in shareholders’ equity which will be amortized over three years.
Research Models and Services. Selling, general and administrative expenses for RMS for the six months ended June 25, 2005 were $28.9 million, an increase of $1.7 million, or 6.4%, compared to $27.2 million for the six months ended June 26, 2004. Selling, general and administrative expenses decreased as a percentage of sales to 11.2% for the six months ended June 25, 2005 from 11.3% for the six months ended June 26, 2004 due to our continued ability to manage costs in line with our sales increase.
Preclinical Services. Selling, general and administrative expenses for the Preclinical Services segment for the six months ended June 25, 2005 were $28.3 million, an increase of $13.2 million, or 87.2%, compared to $15.1 million for the six months ended June 26, 2004. Selling, general and administrative expenses for the six months ended June 25, 2005 decreased to 12.1% of net sales, compared to 13.4% of net sales for the six months ended June 26, 2004 due to greater economies of scale.
Clinical Services. Selling, general and administrative expenses for the Clinical Services segment for the six months ended June 25, 2005 were $12.1 million. Selling, general and administrative expenses for the Clinical Services segment were 18.6% of net sales.
Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various corporate expenses including those associated with pension, executive salaries, stock based compensation and departments such as corporate accounting, legal and investor relations, was $23.1 million for the six months ended June 25, 2005, compared to $15.0 million for the six months ended June 26, 2004. The increase in unallocated corporate overhead for the six months ended June 25, 2005 was due primarily to increased restricted stock expense and stock-based compensation relating to the acquisition of Inveresk.
Amortization of Other Intangibles. Amortization of other intangibles for the six months ended June 25, 2005 was $28.7 million, an increase of $26.3 million, from $2.4 million for the six months ended June 26, 2004. The increased amortization was due to the acquisition of Inveresk.
Preclinical Services. For the six months ended June 25, 2005, amortization of other intangibles for our Preclinical Services segment was $22.6 million, an increase of $20.3 million from $2.3 million for the six months ended June 26, 2004. The increase in amortization of other intangibles was due to the acquisition of Inveresk.
Clinical Services. For the six months ended June 25, 2005, amortization of other intangibles for our Clinical Services segment was $6.0 million, due to the acquisition of Inveresk.
Operating Income. Operating income for the six months ended June 25, 2005 was $95.2 million, an increase of $11.5 million, or 13.8%, from $83.7 million for the six months ended June 26, 2004. Operating income for the six months ended June 25, 2005 was 17.1% of net sales, compared to 23.7% of net sales for
25
the six months ended June 26, 2004. The decrease as a percent of sales was due primarily to the Inveresk related amortization of $26.5 million and the Inveresk stock based compensation charge of $5.8 million.
Research Models and Services. For the six months ended June 25, 2005, operating income for our RMS segment was $85.4 million, an increase of $5.6 million, or 7.0%, from $79.8 million for the six months ended June 26, 2004. Operating income as a percentage of net sales for the six months ended June 25, 2005 was 33.0%, compared to 33.3% for the six months ended June 26, 2004. The decrease in operating income as a percentage of net sales was primarily due to higher cost of products sold and services provided.
Preclinical Services. For the six months ended June 25, 2005, operating income for our Preclinical Services segment was $30.2 million, an increase of $11.2 million, or 59.4%, from $19.0 million for the six months ended June 26, 2004. Operating income as a percentage of net sales decreased to 13.0%, compared to 16.7% of net sales for the six months ended June 26, 2004. The decrease in operating income as a percentage of net sales for the six months ended June 25, 2005 was primarily due to Inveresk related amortization expense of 8.8% of net sales, partially offset by improved capacity utilization.
Clinical Services. For the six months ended June 25, 2005, operating income for our Clinical Services segment was $2.8 million. Operating income as a percentage of net sales was 4.3% for the six months ended June 25, 2005. The operating income as a percentage of net sales includes the Inveresk related amortization of 9.2% of net sales.
Interest Expense. Interest expense for the six months ended June 25, 2005 was $13.0 million, compared to $4.2 million for the six months ended June 26, 2004. The $8.8 million increase was primarily due to the increased borrowing as a result of the Inveresk acquisition.
Income Taxes. Income tax expense for the six months ended June 25, 2005 was $23.3 million, a decrease of $12.9 million compared to $36.2 million for the six months ended June 26, 2004. Our effective tax rate for the six months ended June 25, 2005 was 27.85%. Excluding charges associated with the deferred tax write-off and the benefit from the reversal of the valuation allowance, the effective tax rate for the six months ended June 26, 2004 was 37.5%. The decrease in the effective tax rate was due primarily to the lower effective tax rates for foreign operations.
Net Income. Net income for the six months ended June 25, 2005 was $59.5 million, an increase of $15.6 million from $43.9 million for the six months ended June 26, 2004.
Our backlog for Preclinical Services and Clinical Services was $420.8 million at June 25, 2005. We do not report backlog for the RMS segment because turnaround time from order placement to fulfillment, both for products and services, is rapid. Our preclinical and clinical services are performed over varying times, from a short period of time to extended periods of time, which may be as long as several years. We maintain an order backlog for these segments to track anticipated revenue from studies and projects that either have not started, but are anticipated to begin in the near future, or are in process and have not been completed. We only recognize a study or project in backlog after we have received written evidence of a customer’s intention to proceed with a study or project. Cancelled studies or projects are removed from backlog.
We believe our aggregate backlog as of any date is not necessarily an indicator of our future results for a variety of reasons. First, studies vary in duration. For instance, some studies that are included in 2005 backlog may be completed in the same year, while others may be completed in later years. Second, the scope of studies may change, which may either increase or decrease their value. Third, studies included in backlog may be subject to bonus or penalty payments. Fourth, studies may be terminated or delayed at any time by the client or regulatory authorities. Terminations or delays can result from a number of reasons.
26
Delayed contracts remain in our backlog until a determination of whether to continue, modify or cancel the study has been made.
Liquidity and Capital Resources
The following discussion analyzes liquidity and capital resources by operating, investing and financing activities as presented in our condensed consolidated statements of cash flows.
Our principal sources of liquidity have been our cash flow from operations, our revolving line of credit arrangements and proceeds from our debt and equity offerings.
During the second quarter of 2005, the Company converted all of its $185 million 3.5% senior convertible debentures due February 1, 2022 into 4,759,424 shares of common stock.
Cash and cash equivalents totaled $166.5 million at June 25, 2005, compared to $207.6 million at December 25, 2004.
Net cash provided by operating activities for the six months ended June 25, 2005 and June 26, 2004 was $82.8 million and $68.2 million, respectively. The increase in cash provided by operations was primarily a result of increased earnings before depreciation and amortization. Our days sales outstanding (“DSO”) decreased to 36 days as of June 25, 2005 from 47 days as of June 26, 2004, but increased from 32 days as of December 25, 2004.
Net cash used in investing activities for the six months ended June 25, 2005 and June 26, 2004 was $29.0 million and $30.7 million, respectively. For the six months ended June 25, 2005, we used $24.2 million for capital expenditures. This compared to the six months ended June 26, 2004 during which we paid $11.8 million for capital expenditures and $17.0 million for the acquisition of River Valley Farms. In the six months ended June 25, 2005, we made capital expenditures in RMS of $11.8 million, Preclinical Services of $12.2 million and Clinical Services of $0.3 million. We anticipate that future capital expenditures will be funded by cash provided by operating activities. For fiscal 2005, we have increased our projected capital expenditures from $100 million to $125 million due to the purchase of a Massachusetts preclinical facility in July 2005. We continue to evaluate acquisitions to serve as growth platforms.
Net cash (used in) and provided by financing activities for the six months ended June 25, 2005 and June 26, 2004 was $(83.2) million and $6.1 million, respectively. Proceeds from exercises of employee stock options amounted to $14.0 million and $7.9 million for the six months ended June 25, 2005 and June 26, 2004, respectively. During the six months ended June 25, 2005, we repaid $95.2 million in debt under our credit facility. During the first quarter of 2004, we borrowed and paid back $94.0 million as part of our European reorganization.
Off-Balance Sheet Arrangements
We had no off-balance sheet arrangement during the three months ended June 25, 2005.
Recently Issued Accounting Pronouncements
On December 16, 2004, the Financial Accounting Standards Board issued SFAS No. 123 (revised 2004), “Shared-Based Payment,” which is a revision of SFAS No. 123. SFAS No. 123(R) supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and amends SFAS No. 95, “Statement of Cash Flows.” Generally, the approach in SFAS No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. This revised standard will be effective for us in the first quarter of fiscal year 2006.
27
As permitted by SFAS No. 123, we currently account for share-based payments to employees using APB 25 intrinsic value method and, as such, generally recognize no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123(R)’s fair value method will have an impact on our results of operations, although it will have no impact on our overall financial position. The impact of the modified prospective adoption of SFAS No. 123(R) cannot be estimated at this time because it will depend on levels of share-based payments granted in the future. However, had we adopted SFAS No. 123(R) in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net income and earnings per share.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
Certain of our financial instruments are subject to market risks, including interest rate risk and foreign currency exchange rates. We generally do not use financial instruments for trading or other speculative purposes.
Interest Rate Risk
The fair value of our marketable securities is subject to interest rate risk and will fall in value if market interest rates increase. If market rates were to increase immediately and uniformly by 100 basis points from levels at June 25, 2005, then the fair value of the portfolio would decline by approximately $0.1 million.
On October 15, 2004, we entered into a credit agreement which provides for a $400 million term loan facility and a $150 million revolving facility. Our primary interest rate exposure results from changes in LIBOR or the base rates which are used to determine the applicable interest rates under our term loan and revolving credit facility. Our potential loss over one year that would result from a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate would be approximately $5 million on a pre-tax basis. The book value of our debt approximates fair value.
Foreign Currency Exchange Rate Risk
The Company operates on a global basis and has exposure to some foreign currency exchange rate fluctuations for its earnings and cash flows. This risk is mitigated by the fact that various foreign operations are principally conducted in their respective local currencies. A portion of our foreign operations’ revenue is denominated in U.S. dollars, with the costs accounted for in their local currencies. The Company attempts to minimize its exposure by using certain financial instruments, for purposes other than trading, in accordance with the Company’s overall risk management and our hedge policy. In accordance with our hedge policy, we designate such transactions as hedges as set forth in SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.”
During the second quarter, the Company entered into foreign exchange contracts, principally to hedge the impact of currency fluctuations on customer transactions and certain balance sheet items. Some of these contracts expired during the quarter. At June 25, 2005, the contract amount outstanding was approximately $18 million. The Company recorded a cumulative gain of $0.2 million in accumulated other comprehensive income on the outstanding contract.
Item 4. Controls and Procedures.
Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934 (the “Exchange Act”), the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act are effective as of June 25, 2005 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.
There were no changes in the Company’s internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended June 25, 2005 that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II Other Information
Item 4. Submission of Matters to a Vote of Security Holders
At the Company’s Annual Meeting of Shareholders held on May 9, 2005, the following proposals were adopted by the votes specified below:
(a) The following directors were elected to serve until the Company’s 2006 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:
Number ofShares Voted For
Number ofShares Withheld
James C. Foster
60,236,187
793,647
Stephen D. Chubb
60,160,188
869,646
George E. Massaro
60,973,273
56,561
Linda McGoldrick
60,895,524
134,310
George M. Milne
59,077,605
1,952,229
Douglas E. Rogers
59,107,886
1,921,948
Samuel O. Thier
60,894,328
135,506
William H. Waltrip
59,021,236
2,008,598
(b) Amendments to the Company’s 2000 Incentive Plan (the “Plan”) which provide for the increase of the number of shares available for issuance thereunder by 3,600,000 shares and provide that shares related to cancelled awards would be returned to the Plan following such cancellations and be available for future grants. A total of 42,153,150 shares voted in favor of the amendments, 11,408,169 shares voted against the amendments, and 2,479,986 shares abstained from voting.
(c) The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors for fiscal 2005. A total of 60,668,156 shares voted in favor of the ratification, 347,496 shares voted against the ratification, and 14,182 shares abstained from voting.
Item 6. Exhibits
(a)
Exhibits.
31.1
Certification of the Principal Executive Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
31.2
Certification of the Principal Financial Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
32.1
Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
July 29, 2005
/s/ JAMES C. FOSTER
Chairman, Chief Executive Officer and President
/s/ THOMAS F. ACKERMAN
Thomas F. Ackerman
Corporate Senior Vice Presidentand Chief Financial Officer
31